Ondansetron Sandoz Ltd (Ondansetron)

Ondansetron works by selectively blocking serotonin 5‑HT3 receptors in the chemoreceptor trigger zone of the brain and on vagal afferents in the gastrointestinal tract. This inhibition prevents the neural signaling that triggers the vomiting reflex, providing effective control of emesis.

The dose is individualized by the prescribing clinician based on the type of emetogenic therapy, patient weight, renal and hepatic function, and current clinical guidelines. No fixed regimen is provided here; the prescriber sets the appropriate dose for each patient.

Use of ondansetron during pregnancy or lactation is only recommended when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Clinicians should evaluate each case carefully and consider alternative therapies when appropriate.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with dopamine antagonists such as metoclopramide or antihistamines, ondansetron offers more targeted 5‑HT3 blockade, often resulting in superior control of chemotherapy‑induced nausea and a lower incidence of extrapyramidal side effects, making it a preferred choice in many oncology protocols.

The product should be stored at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the vial in its original packaging until use to maintain stability and potency.

Ondansetron Sandoz Ltd is administered by intravenous injection, typically as a single dose or repeated doses as directed by the prescriber. Administration is performed by a qualified healthcare professional in a clinical setting.

Serious adverse events include QT interval prolongation, which can lead to cardiac arrhythmias such as torsades de pointes, severe allergic reactions (anaphylaxis), and serotonin syndrome when combined with other serotonergic agents. Patients with cardiac conduction disorders or electrolyte imbalances require close monitoring.

Patients with known hypersensitivity to ondansetron or any excipient, individuals with congenital long QT syndrome, and those taking other QT‑prolonging medications without appropriate monitoring should avoid using this product.